Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial ...

一项名为“ASAP（尽可能快）”的试验对国际治疗标准提出了新的见解：对于急性髓系白血病（Acute Myeloid Leukemia, AML）患者，高剂量化疗并非移植前的必要步骤，这意味着患者可以更快地进行移植 [1]。

A systematic review finds AML patients receiving anthracycline remission induction therapy face a significant heart failure ...

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

New research maps how bone marrow changes in acute myeloid leukemia disrupt neutrophil development and boost the risk for ...

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. Researchers at Baylor College of Medicine, University of Veterinary ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...